A public health expert lays out ways GLP-1 drugs could shift American healthcare and public health in the years ahead.
Recap by typeshit. Full story at Forbes.
The 52-year-old actor points to his early 4am workouts and discipline instead of weight loss shots. A celebrity opinion, not new data.
Metz says the drug improved her mobility enough to handle eight Broadway shows a week in "& Juliet". Her account, not a clinical claim.
A general piece on how GLP-1 drugs like Ozempic and Wegovy reshaped weight management in the US. Light on new details.
The broker says Laurus beat 2QFY27 estimates on EBITDA and profit, with its CDMO pipeline and peptide work driving the higher forecasts.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
Ali Ghulam and colleagues report in Genomics & Informatics that a capsule neural network beat CNN and LSTM baselines using dipeptide composition features.
Loading…